Informations générales (source: ClinicalTrials.gov)
LIquid Biopsy to prEdict Responses To First-line immunotherapY in Metastatic Non-small Cell LUNG Cancer
Interventional
N/A
Institut Curie (Voir sur ClinicalTrials)
mai 2021
juin 2030
02 octobre 2025
Patient with histologically proven NSCLC in a metastatic stage, treatment naïve and
eligible for first-line treatment with immune checkpoint inhibitor. Combination with
chemotherapy is possible. Presence of a mutation after NGS analysis is required for ctDNA
follow-up.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT CURIE | 10/04/2025 13:12:14 | Contact (sur clinicalTrials) | |||
| CLCC RENE HUGUENIN INSTITUT CURIE | 10/04/2025 13:11:58 | Contact (sur clinicalTrials) | |||
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| CLCC INSTITUT CURIE | Nicolas GIRARD, PR | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Hopital Ambroise Pare - 92100 - Boulogne-Billancourt 3031137 - France | Etienne GIROUX LE PRIEUR, PR | Contact (sur clinicalTrials) | |||
| Institut Curie - 92210 - Saint-Cloud 2981041 - France | Marie-Ange MASSIANI, DR | Contact (sur clinicalTrials) | |||
Critères
Tous
1. Histologically-proven NSCLC.
2. Age ≥ 18 years.
3. Advanced or metastatic stage IV.
4. Treatment-naïve patient.
5. Eligibility to first-line treatment with immune checkpoint inhibitor.
6. Measurable disease according to RECIST 1.1 criteria on CT-Scan.
7. Availability of expression of PD-L1 at immunohistochemistry analysis of the tumor
biopsy.
8. No ALK or EGFR gene alteration.
9. Availability of tumor tissue for NGS analysis (7 slides).
10. PS 0 or 1.
11. Signed informed consent of the patient.
Exclusion Criteria:
1. No social security affiliation.
2. Person under legal protection.
3. Pregnant and breastfeeding women.
Patients can participate to another clinical trial that is not modifying immunotherapy or
immunotherapy/chemotherapy treatment nor study follow-up ; after investigator's
information